Get started
NANJING KING-FRIEND BIOCHEMICAL PHARMACEUTICALNN

NANJING KING-FRIEND BIOCHEMICAL PHARMACEUTICAL

14.38CNYD
+0.19+1.34%
At close at Mar 21, 09:14 GMT
CNY
No trades
See on Supercharts
Overview
Financials
News Discussions Technicals Forecast Seasonals

603707 fundamentals

Key facts

Market capitalization‪23.19 B‬CNY
Dividend yield (indicated)0.70%
Price to earnings Ratio (TTM)—
Basic EPS (TTM)−0.26CNY
Founded2000
Employees (FY)‪1.45 K‬
CEOYong Qun Tang
Websitenkf-pharma.com
About

Nanjing King-friend Biochemical Pharmaceutical Co., Ltd. is a holding company that engages in the research, development, manufacture and sale of biochemical pharmaceutical products. It offers injections such as heparin sodium, low molecular weight heparin, and heparin sodium raw material. The company was founded on October 16, 2000 and is headquartered in Nanjing, China.

Ownership
‪‪1.62 B‬‬
Closely held shares
‪‪1.17 B‬‬ (72.59%)
Free Float shares
‪‪442.77 M‬‬ (27.41%)
Closely held shares
‪‪1.17 B‬‬ (72.59%)
Free Float shares
‪‪442.77 M‬‬ (27.41%)
Capital structure
Market cap
‪‪23.19 B‬‬
Debt
‪‪2.31 B‬‬
Minority interest
‪‪−3.48 M‬‬
Cash & equivalents
‪‪1.95 B‬‬
Enterprise value
‪‪23.54 B‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪23.19 B‬‬
Price to earning ratio (P/E)
—
Price to sales ratio (P/S)
5.97x
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
—
Price to sales ratio (P/S)
5.97x
Valuation ratios
‪0.00‬
‪1.60‬
‪3.20‬
‪4.80‬
‪6.40‬
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
‪0.00‬
‪5.50‬
‪11.00‬
‪16.50‬
‪22.00‬
P/E
P/S

Growth and Profitability

Company’s recent performance and margins

Performance
‪−150%‬
‪−100%‬
‪−50%‬
‪0%‬
‪50%‬
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
‪‪−1.20 B‬‬
‪‪−600.00 M‬‬
‪0.00‬
‪‪600.00 M‬‬
‪‪1.20 B‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪0.00‬
‪‪250.00 M‬‬
‪‪500.00 M‬‬
‪‪750.00 M‬‬
‪‪1.00 B‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪0.00‬
‪‪250.00 M‬‬
‪‪500.00 M‬‬
‪‪750.00 M‬‬
‪‪1.00 B‬‬

Revenue breakdown

Revenue streams and regions a business earns money from

By source/business
Period: 2023
Preparation
Standard Heparin API
Contract Development and Manufacturing Organization and Other Products
Other Business
By country
Period: 2023
Foreign
China

Estimates

Revenue and Earnings forecasts and estimates accuracy

Revenue
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪0.00‬
‪‪300.00 M‬‬
‪‪600.00 M‬‬
‪‪900.00 M‬‬
‪‪1.20 B‬‬
Actual
Earnings
Next:Apr 29, 2025
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪0.00‬
‪0.03‬
‪0.06‬
‪0.09‬
‪0.12‬
Estimate

Dividends

Dividend yield, history and sustainability

Dividend summary
−38.15%
Payout ratio (TTM)
Dividend yield TTM
0.70%
Last payment
0.10
Last ex-date
Jul 8, 2024
Dividend history
‪0.25%‬
‪0.37%‬
‪0.49%‬
‪0.61%‬
‪0.73%‬
2019
2020
2021
2022
2023
‪0.00‬
‪0.04‬
‪0.08‬
‪0.12‬
‪0.16‬
Dividends per share (FY)
Dividend yield (FY) %

Financial health

Financial position and solvency of the company

Debt level and coverage
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
‪0.00‬
‪‪900.00 M‬‬
‪‪1.80 B‬‬
‪‪2.70 B‬‬
‪‪3.60 B‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
‪0.00‬
‪‪2.00 B‬‬
‪‪4.00 B‬‬
‪‪6.00 B‬‬
‪‪8.00 B‬‬
Assets
Liabilities